Deepa Shanmugham1*, Ravikumar Sambantham2
1Department of Obstetrics and Gynaecology, India
2Research Scientist and Head, Centre for Biomedical Research, India
*Corresponding author: Deepa Shanmugham, Department of Obstetrics and Gynaecology, Pondicherry, India
Submission: April 18, 2022; Published: July 05, 2022
Volume2 Issue2July , 2022
Keywords:Polycystic ovarian syndrome; Hyperandrogenism; Microbiome; Insulin resistance
Keywords:PCOS: Polycystic Ovarian Syndrome; LH: Luteinizing Hormone; FSH: Follicle-Stimulating Hormone; SHBG: Sex Hormone-Binding Globulin; DOGMA: Dysbiosis of Gut Microbiota
Polycystic Ovarian Syndrome (PCOS) is a complex metabolic, endocrine and reproductive disorder that results in the overproduction of androgens and is associated with insulin resistance. PCOS is one of the most common endocrine disorders in reproductive-aged women and affects 4-12 % [1]. PCOS is a chronic condition with manifestations that begin most commonly in adolescence with menstrual irregularity and hyperandrogenism, with a transition over time into problems including infertility and metabolic complications.
The predominantly European definition of PCOS requires an ultrasonically diagnosed
typical morphological appearance of the ovary usually according to the criteria of Adams et
al. [2]. The Polycystic ovary morphology is defined by ESHRE/ASRM consensus criteria as
at least one ovary with >=12 follicles of 2-9mm (between 2-5 days of the cycle ) or ovarian
volume greater than 10ml in the absence of a cyst or dominant follicle >10mm, established
with ultrasound examination of ovaries [3]. The European Society for Human Reproduction
and Embryology (ESHRE) and the American Society for Reproductive Medicine, convened in
Rotterdam, The N Netherlands, in 2003, concluded that diagnosis of PCOS should be based on
at least two of the three major criteria including
a) Oligo/Anovulation
b) Clinical or biochemical signs of hyperandrogenism and
c) Polycystic morphology on ultrasound, after the exclusion of other pathologies with a
similar clinical presentation such as congenital adrenal hyperplasia,
Cushing’s syndrome and androgen-secreting tumours [4] The 2018 international PCOS guideline updated the Rotterdam criteria and now recommends applying Oligo Anovulation and Hyper Androgeneism while avoiding Polycystic ovarian morphology for PCOS diagnosis in adolescents [5]
Although the underlying cause of PCOS is unknown, a genetic basis that is both multifactorial and polygenic is suspected, as there is a well-documented aggregation of the syndrome within families [6]. Clinical and in vitro studies of human ovarian theca cells have suggested dysregulation of the CYP11a gene in patients with PCOS, which encodes the enzyme that performs rate limiting step in steroid biosynthesis [7]. In addition, the insulin receptor gene in chromosome 19p13.2 may be involved. A recent mathematical review of microarray data in women with PCOS identified 504 protein nodes and 1048 interactions among them and stated that there was a cell cycle protein in this network yet to be identified [8]. Growing evidence supports the concept that PCOS is associated with increased oxidative stress and systemic inflammation. When compared to healthy control subjects, women with PCOS have increased markers of lipid peroxidation, elevated levels of C Reactive proteins, Inflammatory cytokines as well as a higher concentration of blood lymphocytes and monocytes [9].
The key elements involved in the pathophysiology are
a) Inappropriate Gonadotropin secretion
b) Insulin resistance
c) Increased circulating androgens
d) Decreased sex hormone-binding globulin
e) Anovulation
Inappropriate gonadotropin secretion
Alteration in the pulsatile GnRH pulsatility leads to preferential production of Luteinizing Hormone (LH) compared with Follicle- Stimulating Hormone (FSH). It is currently unknown whether hypothalamic dysfunction is the primary cause of PCOS or is secondary to abnormal steroid feedback [10].
Insulin resistance
Decreased insulin sensitivity is due to post binding abnormality in insulin-receptor mediated signal transduction [10] .Both lean and obese PCOS patients are found to be more insulin resistant than nonaffected weight-matched controls [11].
Increased androgens
Both insulin and LH stimulate androgen production by theca cells of the ovary [7]. The affected ovaries secret elevated levels of testosterone and androstenedione. Specifically, free testosterone levels are noted in 70 to 80% of women with PCOS and 25 to 65% exhibit elevated levels of DHEAS [12,13].
Decreased Sex Hormone-Binding Globulin (SHBG)
The synthesis of SHBG is suppressed by insulin and androgens in PCOS patients. This leads to increased free testosterone to develop hyperandrogenism [14].
Anovulation
Although the precise mechanism is unclear, hypersecretion of LH and insulin resistance lead to anovulation and a substantial number of patients resume ovulatory cycles when treated with metformin.
In recent years, the relationship between PCOS and gut microbiota has been the interest in the studies involving the pathogenesis of PCOS. Studies have shown that there is an alteration in the general composition of gut microbiome in patients with PCOS and changes in and diversity of microbiota [15,16]. The Dysbiosis of Gut Microbiota (DOGMA) hypothesis suggested that an imbalance of intestinal flora with increased intestinal permeability results in activation of immune system with inflammatory response, which leads to insulin resistance [17]. Further studies are being done to explore the role of the gut microbiome in PCOS.
The clinical management of women with PCOS should be focussed on her individual problems. Diet and exercise are key to symptom control. Even a modest amount (5% of body weight) of weight loss (diet & exercise) can result in restoration of normal ovulatory cycles. It has been shown that metformin ameliorates hyperandrogenism and abnormalities of gonadotropin secretion in women with PCOS and can restore menstrual cyclicity and fertility [17] Pharmacological ovulation induction can be used to induce ovulation, but it is generally second line after intensive lifestyle therapy in overweight or obese women with PCOS. Clomiphene Citrate (CC), an oral ovulation induction agent in use for over 40 years, is generally considered to be the first-line pharmacological therapy to improve fertility outcomes in anovulatory women with PCOS.
© 2022 Deepa Shanmugham. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.